Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non response to current treatment options.
Quote | Basilea Pharm Ag Akt Shs (OTCMKTS:BPMUF)
Last: | $40.75 |
---|---|
Change Percent: | 0.0% |
Open: | $40.75 |
Close: | $40.75 |
High: | $40.75 |
Low: | $40.75 |
Volume: | 5 |
Last Trade Date Time: | 02/13/2024 03:00:00 am |
News | Basilea Pharm Ag Akt Shs (OTCMKTS:BPMUF)
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the an...
2024-02-13 09:18:40 ET More on Basilea Pharmaceutica AG Historical earnings data for Basilea Pharmaceutica AG Financial information for Basilea Pharmaceutica AG Read the full article on Seeking Alpha For further details see: Basilea Pharmaceutica AG GAAP ...
Message Board Posts | Basilea Pharm Ag Akt Shs (OTCMKTS:BPMUF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Basilea Pharmaceutic (BPMUF) Headlines Astellas Secures Exclusive Rights to Co | Stock_Tracker | investorshangout | 03/09/2014 8:12:57 AM |
chartguy89: BPMUF 140.00 Stock Charts $BPMUF 1 Month Chart | chartguy89 | investorshangout | 03/06/2014 9:44:19 AM |
Stock_Tracker: BPMUF Recent News Astellas Secures Exclusive Rights to Commercialize Isavuconazole in | Stock_Tracker | investorshangout | 03/03/2014 8:23:31 AM |
chartguy89: BPMUF Stock Charts Monday, February 24, 2014 at 12:34:42 AM $BPMUF Last: -2.55 | chartguy89 | investorshangout | 02/24/2014 5:34:54 AM |
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the an...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q4 2023